| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gary Sachs, Raymond Sanchez, Ronald Marcus, Elyse Stock, Robert McQuade, William Carson, Neveen Abou-Gharbia, Cheryl Impellizzeri, Stephen Kaplita, Linda Rollin, Taro Iwamot. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Journal of psychopharmacology (Oxford, England). vol 20. issue 4. 2006-08-18. PMID:16401666. |
this study compares the efficacy, safety, and tolerability of a partial dopamine agonist, aripiprazole, with placebo in the treatment of patients with bipolar i disorder experiencing an acute manic or mixed episode. |
2006-08-18 |
2023-08-12 |
Not clear |
| Cristina Cosi, Elisabeth Carilla-Durand, Marie Bernadette Assié, Anne Marie Ormiere, Mireille Maraval, Nathalie Leduc, Adrian Newman-Tancred. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. European journal of pharmacology. vol 535. issue 1-3. 2006-06-21. PMID:16554049. |
partial agonist properties of the antipsychotics ssr181507, aripiprazole and bifeprunox at dopamine d2 receptors: g protein activation and prolactin release. |
2006-06-21 |
2023-08-12 |
human |
| Cristina Cosi, Elisabeth Carilla-Durand, Marie Bernadette Assié, Anne Marie Ormiere, Mireille Maraval, Nathalie Leduc, Adrian Newman-Tancred. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. European journal of pharmacology. vol 535. issue 1-3. 2006-06-21. PMID:16554049. |
we compared the effects of the new antipsychotic agents ssr181507 ((3-exo)-8-benzoyl-n-[[(2 s)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine monohydrochloride), bifeprunox (du127090: 1-(2-oxo-benzoxazolin-7-yl)-4-(3-biphenyl)methylpiperazinemesylate) and slv313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-piperazine) with those of aripiprazole (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-butyloxy)-3,4-dihydro-2(1 h)-quinolinone), clozapine and haloperidol, on functional measures of dopamine d2 receptor activity in vitro and in vivo: [35s]-gtpgammas binding to membranes from sf9 insect cells expressing human dopamine d2 long (hd2 l) receptors, and serum prolactin levels in the rat. |
2006-06-21 |
2023-08-12 |
human |
| Cristina Cosi, Elisabeth Carilla-Durand, Marie Bernadette Assié, Anne Marie Ormiere, Mireille Maraval, Nathalie Leduc, Adrian Newman-Tancred. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. European journal of pharmacology. vol 535. issue 1-3. 2006-06-21. PMID:16554049. |
these data show that (1) ssr181507, aripiprazole and bifeprunox, but not slv313, are partial agonists at dopamine hd2 l receptors in vitro; (2) ssr181507, bifeprunox and aripiprazole exhibit reduced prolactin release in vivo compared with drugs that are neutral antagonists at dopamine d2 receptors. |
2006-06-21 |
2023-08-12 |
human |
| Liesbeth A Bruins Slot, Luc De Vries, Adrian Newman-Tancredi, Didier Cussa. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. European journal of pharmacology. vol 534. issue 1-3. 2006-06-07. PMID:16497294. |
at dopamine d2s receptors, partial agonist activity (% effect of 10 microm dopamine) was observed for bifeprunox (76), ssr181507 (66) and aripiprazole (59). |
2006-06-07 |
2023-08-12 |
human |
| Liesbeth A Bruins Slot, Luc De Vries, Adrian Newman-Tancredi, Didier Cussa. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. European journal of pharmacology. vol 534. issue 1-3. 2006-06-07. PMID:16497294. |
amongst the dopamine d2/serotonin 5-ht1a receptor compounds, aripiprazole acts as a partial dopamine d2s and serotonin 5-ht1a receptor agonist. |
2006-06-07 |
2023-08-12 |
human |
| Konstantinos N Fountoulakis, Melina Siamouli, Sotiris Kantartzis, Panagiotis Panagiotidis, Apostolos Iacovides, George St Kaprini. Acute dystonia with low-dosage aripiprazole in Tourette's disorder. The Annals of pharmacotherapy. vol 40. issue 4. 2006-06-01. PMID:16569800. |
to report a case of an acute dystonic episode in a patient with tourette's disorder (td) treated with the partial dopamine agonist aripiprazole. |
2006-06-01 |
2023-08-12 |
Not clear |
| G Gründer, M Kungel, M Ebrecht, T Göröcs, S Model. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry. vol 39 Suppl 1. 2006-05-24. PMID:16508892. |
aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. |
2006-05-24 |
2023-08-12 |
Not clear |
| G Gründer, M Kungel, M Ebrecht, T Göröcs, S Model. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry. vol 39 Suppl 1. 2006-05-24. PMID:16508892. |
aripiprazole is the first approved atypical antipsychotic with a mechanism of action that exerts a partial agonism with high affinity at dopamin d2- and serotonin-5-ht1a-receptors as well as an antagonism at serotonin-5-ht2a-receptors. |
2006-05-24 |
2023-08-12 |
Not clear |
| Suzana Uzun, Oliver Kozumplik, Ninoslav Mimica, Vera Folnegović-Smal. Aripiprazole: an overview of a novel antipsychotic. Psychiatria Danubina. vol 17. issue 1-2. 2006-02-15. PMID:16395846. |
aripiprazole exhibits high affinity for dopamine d2 and d3, serotonin 5-ht1a and 5-ht2a receptors, moderate affinity for dopamine d4, serotonin 5-ht2c and 5-ht7, alpha1-adrenergic and histamine h1 receptors. |
2006-02-15 |
2023-08-12 |
Not clear |
| Jeffrey S Simon, Charles B Nemerof. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. The Journal of clinical psychiatry. vol 66. issue 10. 2006-02-09. PMID:16259533. |
to determine the efficacy and tolerability of aripiprazole, a dopamine d2 and 5-ht1a receptor partial agonist, as augmentation of antidepressant treatment of partially responding and nonresponding patients with major depressive disorder. |
2006-02-09 |
2023-08-12 |
Not clear |
| Tsuyoshi Hirose, Tetsuro Kikuch. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. The journal of medical investigation : JMI. vol 52 Suppl. 2006-02-03. PMID:16366516. |
aripiprazole, a novel antipsychotic agent: dopamine d2 receptor partial agonist. |
2006-02-03 |
2023-08-12 |
Not clear |
| Alessandro Zocchi, Daniela Fabbri, Christian A Heidbrede. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neuroscience letters. vol 387. issue 3. 2005-12-20. PMID:16023290. |
aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. |
2005-12-20 |
2023-08-12 |
mouse |
| Alessandro Zocchi, Daniela Fabbri, Christian A Heidbrede. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neuroscience letters. vol 387. issue 3. 2005-12-20. PMID:16023290. |
aripiprazole, a novel atypical antipsychotic drug, can significantly increase dopamine (da) levels in the prefrontal cortex of rats, but only at low doses below 1mg/kg. |
2005-12-20 |
2023-08-12 |
mouse |
| Marie-Bernadette Assié, Véronique Ravailhe, Valérie Faucillon, Adrian Newman-Tancred. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. The Journal of pharmacology and experimental therapeutics. vol 315. issue 1. 2005-11-28. PMID:15987834. |
haloperidol, nemonapride, and the d2 partial agonists, aripiprazole and bifeprunox, did not significantly alter dopamine release. |
2005-11-28 |
2023-08-12 |
rat |
| Franca Centorrino, Kate V Fogarty, Paola Cimbolli, Paola Salvatore, Terri-Ann Thompson, Gabriele Sani, Stephanie L Cincotta, Ross J Baldessarin. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. Journal of psychiatric practice. vol 11. issue 4. 2005-10-04. PMID:16041234. |
aripiprazole is the first dopamine d2 receptor partial-agonist approved for treatment of schizophrenia. |
2005-10-04 |
2023-08-12 |
Not clear |
| Yoshihiro Tadori, Takashi Miwa, Katsura Tottori, Kevin D Burris, Arlene Stark, Toyoki Mori, Tetsuro Kikuch. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European journal of pharmacology. vol 515. issue 1-3. 2005-08-16. PMID:15894311. |
aripiprazole's low intrinsic activities at human dopamine d2l and d2s receptors render it a unique antipsychotic. |
2005-08-16 |
2023-08-12 |
human |
| Yoshihiro Tadori, Takashi Miwa, Katsura Tottori, Kevin D Burris, Arlene Stark, Toyoki Mori, Tetsuro Kikuch. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European journal of pharmacology. vol 515. issue 1-3. 2005-08-16. PMID:15894311. |
aripiprazole is the first clinically approved atypical antipsychotic agent having dopamine d2 receptor partial agonist activities. |
2005-08-16 |
2023-08-12 |
human |
| Yoshihiro Tadori, Takashi Miwa, Katsura Tottori, Kevin D Burris, Arlene Stark, Toyoki Mori, Tetsuro Kikuch. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European journal of pharmacology. vol 515. issue 1-3. 2005-08-16. PMID:15894311. |
to evaluate aripiprazole's agonist and antagonist properties, we established a chinese hamster ovary cell line expressing high and low densities of the long and short isoforms of human dopamine d2 receptors, then compared its properties with 7-{3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy}-2(1h)-quinolinone (opc-4392), s(-)-3-(3-hydroxyphenyl)-n-n-propylpiperidine ((-)-3-ppp), and terguride (other partial agonists) using forskolin-stimulated camp accumulation as an index. |
2005-08-16 |
2023-08-12 |
human |
| E Sherwood Brown, Jala Jeffress, Joshua D M Liggin, Monica Garza, Laura Bear. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. The Journal of clinical psychiatry. vol 66. issue 6. 2005-08-04. PMID:15960570. |
aripiprazole is an atypical antipsychotic that is approved for the treatment of mania and that has a novel mechanism of action, acting as a dopamine-2 receptor partial agonist, thereby increasing dopamine release in some parts of the brain and decreasing dopa-mine release in other brain regions. |
2005-08-04 |
2023-08-12 |
Not clear |